Overview
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Status:
Completed
Completed
Trial end date:
2010-10-01
2010-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local therapies.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AmgenTreatments:
Motesanib diphosphate
Criteria
Inclusion Criteria: - Histologically confirmed locally advanced or metastatic thyroidcancer - Measurable disease - Normal blood pressure (if history of hypertension, blood
pressure must be controlled with medication) - Evidence of disease progression within 6
months before starting study (for differentiated thyroid cancer subjects) - Evidence of
disease progression within 6 months before starting study OR symptomatic disease (for
medullary thyroid cancer subjects) - Not a candidate for surgical resection, external beam
radiotherapy, radioiodine therapy, or other local therapy - At least 18 years of age
Exclusion Criteria: - Undifferentiated/anaplastic thyroid cancer - Untreated or symptomatic
brain metastases - Prior malignancy, unless cured with treatment and no evidence of disease
for greater than or equal to 3 years before starting study (history of thyroid cancer, in
situ cervical cancer, or basal cell cancer of skin are exceptions) - Myocardial infarction
or any unstable cardiac condition (e.g., congestive heart failure, unstable angina) within
1 year before starting study - Arterial thrombosis or deep vein thrombosis within 1 year
before starting study